Centene cetuximab coverage & prior auth update

Coverage Criteria for Cetuximab (Erbitux)

Initial Therapy — Head and Neck SCC

Covered when ALL of the following are met

HNSCC initial criteria: 1. Diagnosis of head and neck squamous cell carcinoma (see Appendix D for subtypes by location); 2. Prescribed by or in consultation with an oncologist; 3. Age >= 18 years; 4. One of the following: a) disease is advanced, recurrent, unresectable, or metastatic; b) member is receiving reirradiation with concurrent radiotherapy; 5. Prescribed as either: a) single agent; or b) in combination with platinum-based therapy (e.g., cisplatin or carboplatin), nivolumab (Opdivo), pembrolizumab (Keytruda), paclitaxel, or docetaxel (if cisplatin-ineligible); 6. Dose meets one of the following: a) initial dose 400 mg/m2 followed by 250 mg/m2 weekly; b) 500 mg/m2 every 2 weeks; or c) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence); 7. Prescribed regimen is FDA-approved or recommended by NCCNage >=18

Prior authorization may be required for platinum-based therapies

Initial Therapy — Colorectal Cancer

Covered when ALL of the following are met

CRC initial criteria: 1. Diagnosis of advanced, recurrent, or metastatic colorectal cancer; 2. Prescribed by or in consultation with an oncologist; 3. Age >= 18 years; 4. Tumor meets one of: a) KRAS/NRAS/BRAF wild-type (no activating mutations); b) BRAF V600E mutation positive; c) KRAS G12C mutation positive; d) deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H); e) POLE/POLD1 mutation positive with ultrahypermutated phenotype (e.g., TMB > 50 mut/Mb); 5. Prescribed as one of: a) single agent; b) in combination with FOLFIRI, FOLFOX, or CapeOX; c) in combination with irinotecan following prior therapy; d) if BRAF V600E positive: in combination with encorafenib (Braftovi) with or without FOLFOX; e) if KRAS G12C positive: in combination with sotorasib (Lumakras) or adagrasib (Krazati) following prior therapy; 6. For KRAS/NRAS/BRAF wild-type colon cancer with unresectable synchronous or metachronous liver and/or lung metastases: tumor must be left-sided only (see Appendix E); 7. For dMMR/MSI-H or POLE/POLD1 mutation positive disease: member is ineligible for or has progressed on checkpoint inhibitor immunotherapy; 8. Dose meets one of: a) initial dose 400 mg/m2 followed by 250 mg/m2 weekly; b) 500 mg/m2 every 2 weeks; c) dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 9. Prescribed regimen is FDA-approved or recommended by NCCNage >=18

Policy excludes RAS‑mutant CRC unless specific allowed mutations listed; prior authorization and line‑of‑therapy rules per policy updates

Initial Therapy — NSCLC (off-label)

Covered when ALL of the following are met

NSCLC off-label criteria: 1. Diagnosis of recurrent, advanced, or metastatic non-small cell lung cancer; 2. Prescribed by or in consultation with an oncologist; 3. Age >= 18 years; 4. Tumor is positive for an EGFR sensitizing mutation (exon 19 deletion or exon 21 L858R, or EGFR S768I, L861Q, and/or G719X); 5. Prescribed in combination with afatinib (Gilotrif) as subsequent therapy; 6. Disease has progressed on or after an EGFR tyrosine kinase inhibitor (EGFR TKI) therapy; 7. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 8. Prescribed regimen is FDA-approved or recommended by NCCNage >=18

Prior authorization may be required for Gilotrif; disease progression requirement simplified in latest updates

Initial Therapy — Penile Cancer (off-label)

Covered when ALL of the following are met

Penile cancer off-label criteria: 1. Diagnosis of metastatic or recurrent penile cancer; 2. Prescribed by or in consultation with an oncologist; 3. Age >= 18 years; 4. Prescribed as a single agent; 5. Prescribed as subsequent-line systemic therapy; 6. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 7. Prescribed regimen is FDA-approved or recommended by NCCNage >=18

Off-label use requires supporting evidence

Initial Therapy — Squamous Cell Skin Cancer (off-label)

Covered when ALL of the following are met

SCC of skin off-label criteria: 1. Diagnosis of squamous cell skin cancer; 2. Prescribed by or in consultation with an oncologist; 3. Age >= 18 years; 4. Prescribed as either: a) single agent; or b) if member is ineligible for or progressed on immune checkpoint inhibitors and clinical trials: in combination with carboplatin and paclitaxel; 5. Disease is advanced, unresectable, high-risk, recurrent, metastatic, inoperable, or not fully resectable; 6. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence); 7. Prescribed regimen is FDA-approved or recommended by NCCNage >=18

Off-label use requires supporting evidence; approval durations vary by line of business

Continuation Therapy

Covered when ALL of the following are met

Continued therapy criteria: 1. Member is currently receiving cetuximab via the Centene benefit, or documentation supports current receipt for at least 30 days; 2. Member is responding positively to therapy; 3. If request is for a dose increase, meets one of: a) for HNSCC or CRC, new dose does not exceed 250 mg/m2 weekly or 500 mg/m2 every 2 weeks; b) new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence); 4. Prescribed regimen is FDA-approved or recommended by NCCN>=30 days current therapy

Approval durations per line of business apply (Medicaid/HIM 12 months; Commercial 6 months or to member renewal date, whichever is longer)

High-level coverage criteria excerpts

Coverage is provided according to FDA‑approved indications and NCCN‑aligned criteria with specified biomarker and anatomic qualifiers.

Contraindications/Warnings: No contraindications reported; boxed warnings for infusion reactions and cardiopulmonary arrest must be considered.

Providers must monitor infusion reactions per PI

CRC — sidedness and biomarker restrictions: Cetuximab use in KRAS/NRAS/BRAF wild-type colon cancer is recommended only for left-sided tumors when used for unresectable synchronous or metachronous liver and/or lung metastases; left side defined as splenic flexure to rectum per NCCN (see Appendix E).

Policy updates modified left-sided requirement to include metachronous metastases

NSCLC — EGFR sensitizing mutations: For NSCLC, cetuximab use specifies sensitizing EGFR mutations: exon 19 deletion, exon 21 L858R, S768I, L861Q, and/or G719X.

Aligns with NCCN-specified mutations

Requests for non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient documentation demonstrating efficacy and safety in accordance with applicable off‑label use policies.

Off‑label use of cetuximab must be supported by the applicable off‑label use policy for the member’s line of business — CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid) — or by other evidence of coverage documents showing adequate efficacy and safety.

Erbitux (cetuximab) is not indicated for treatment of Ras‑mutant colorectal cancer or when Ras mutation status is unknown. Coverage is limited to the biomarker profiles specified in the policy (for example, K‑Ras wild‑type or other listed mutations such as BRAF V600E), and the limitation of use in the FDA label must be observed when assessing medical necessity.

If a request is for a non‑FDA approved indication and the provider does not submit the required documentation per the off‑label use policies referenced in this policy, the request may be determined not medically necessary and denied.

Approved Regimens and Combinations

Indication	Regimen / Setting	Coverage Status
Head and neck squamous cell carcinoma (HNSCC)
Erbitux with radiation for locally or regionally advanced HNSCC (initial treatment)
Erbitux + platinum-based therapy with fluorouracil (5‑FU) for recurrent or metastatic HNSCC (first‑line)
Erbitux as single agent for recurrent or metastatic HNSCC progressing after platinum‑based therapy (subsequent/salvage)

Indication	Regimen / Setting	Coverage Status
Metastatic colorectal cancer (KRAS/NRAS/BRAF wild‑type)
Erbitux in combination with FOLFIRI for first‑line treatment
Metastatic colorectal cancer (irinotecan‑refractory)
Erbitux + irinotecan for irinotecan‑refractory disease
Metastatic colorectal cancer after oxaliplatin and irinotecan failure or intolerance
Erbitux as single agent after failure of oxaliplatin‑ and irinotecan‑based chemotherapy
BRAF V600E mutation‑positive metastatic CRC
Erbitux (cetuximab) in combination with encorafenib (with or without FOLFOX) for BRAF V600E‑mutant CRC after prior therapy

Indication	Regimen / Setting	Coverage Status
Non‑small cell lung cancer (off‑label) with EGFR sensitizing mutations
Erbitux in combination with afatinib (Gilotrif) as subsequent therapy after progression on an EGFR TKI

Indication	Regimen / Setting	Coverage Status
Metastatic or recurrent penile cancer (off‑label)
Erbitux as single agent as subsequent‑line systemic therapy (requires supporting evidence/NCCN guidance)
Squamous cell skin cancer (off‑label)
Erbitux as single agent OR, if ineligible for or progressed on checkpoint inhibitors and clinical trials, in combination with carboplatin + paclitaxel (requires supporting evidence/NCCN guidance)

Schedule	Dose	Notes / Combinations
Weekly (standard)
Initial 400 mg/m2 IV once, then 250 mg/m2 IV weekly thereafter
May be combined per NCCN recommendations (e.g., with FOLFOX, CapeOX, platinum‑based regimens, or checkpoint inhibitors where specified).
Biweekly (alternative)
500 mg/m2 IV every 2 weeks (initial and subsequent doses)
Accepted alternative schedule; dosing must be within specified limits or supported by guidelines/literature.

Indication	Regimen	Coverage Status
BRAF V600E mutation‑positive metastatic colorectal cancer
Cetuximab (Erbitux) in combination with encorafenib (Braftovi) with or without FOLFOX per updated guidance

Required Biomarker and Mutation Status

KRAS/NRAS/BRAF — wild-type or listed mutations

RequirementKRAS/NRAS/BRAF must be wild-type (no activating mutations) for specified CRC indications, or specific mutations (BRAF V600E or KRAS G12C) may qualify when listed

ContextUsed to determine eligibility for cetuximab in metastatic CRC: wild-type tumors qualify for standard cetuximab regimens; BRAF V600E or KRAS G12C define alternative pathways with specific combination therapies

NotesPolicy excludes Ras‑mutant CRC unless the specific mutation is listed as qualifying (e.g., KRAS G12C or BRAF V600E)

K‑Ras — wild‑type (FDA‑approved test)

RequirementK‑Ras must be wild‑type as determined by an FDA‑approved test for the FDA CRC indication

Implication

Billing Codes and Dosing Information

Covered drug codesHCPCS

HCPCS JXXXX

Cetuximab (Erbitux) drug admin code placeholder — specific HCPCS codes not listed in this section

HCPCS CodesHCPCS

J9055

Injection, cetuximab, 10 mg

Initial/maximum dosing

Initial dosing optionsInitial: 400 mg/m2 IV followed by 250 mg/m2 weekly OR 500 mg/m2 IV every 2 weeks

Continuation/maximumContinuation maximum: 250 mg/m2 weekly or 500 mg/m2 every 2 weeks

ContextDosing schedules apply to HNSCC and CRC; deviations must be supported by guidelines or literature

Dosing regimens — weekly or biweekly

Weekly regimenInitial 400 mg/m2 IV then 250 mg/m2 IV weekly thereafter

Biweekly regimen500 mg/m2 IV every 2 weeks (initial and subsequent doses)

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for cetuximab. Provider must obtain approval before initiating therapy and ensure the requested regimen and any combination agents have necessary prior authorizations as applicable.

Prior authorization required for cetuximab (HCPCS J9055).
Provider must ensure combination agents (e.g., platinum-based therapy, Braftovi®, Lumakras®, Krazati®, EGFR TKIs) have any required prior authorizations.

Denial Risk

Documentation-based Denial Risk

Failure to submit sufficient supporting clinical documentation may result in denial of the request. Requests for non‑FDA approved indications without adequate evidence per off‑label policies may be considered not medically necessary.

Denial risk if office notes, labs, pathology, molecular testing (e.g., KRAS/NRAS/BRAF, dMMR/MSI, POLE/POLD1, EGFR) or other clinical information are not provided.

Line of Therapy Designations

first-line | second-line | salvage — 1 top-level node

Line of therapy: Allowed as initial therapy, subsequent therapy, or salvage as specified per indication: e.g., Erbitux with radiation or chemotherapy for HNSCC (initial); first-line for metastatic CRC in combination with FOLFIRI or other listed combinations; single agent for subsequent-line HNSCC or CRC after platinum/oxaliplatin/irinotecan failure; off-label uses (NSCLC, penile, squamous cell skin) are generally subsequent-line where noted.

first-line | second-line | salvage — 1 top-level node (additional revisions/contexts)

Line of therapy notes: Policy updates and annual reviews modified prior therapy and combination requirements: examples include allowance of Erbitux + encorafenib with or without FOLFOX for BRAF V600E without prior therapy, clarification of POLE/POLD1 ultrahypermutated phenotype requirement, simplification of NSCLC progression language, and updated approval durations by line of business.

Background and Drug Information

Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) antagonist indicated for certain head and neck squamous cell carcinomas (HNSCC) and for select forms of colorectal cancer (CRC). The FDA label includes use with radiation for locally/regionally advanced HNSCC, use in combination with platinum‑based therapy and fluorouracil for recurrent/metastatic HNSCC, and single‑agent use after platinum progression. For CRC, the label supports use in K‑Ras wild‑type, EGFR‑expressing metastatic disease (including in combination with FOLFIRI or as a single agent in specific refractory settings) and in combination with encorafenib for BRAF V600E‑mutant metastatic CRC after prior therapy. Providers should also note boxed warnings for infusion reactions and cardiopulmonary arrest and follow dosing and monitoring guidance in the prescribing information.

Definitions and Abbreviations

dMMR/MSI‑H — definition

DefinitiondMMR/MSI‑H = deficient mismatch repair/microsatellite instability‑high

LocationDefined in Appendix A of the policy's appendices/definitions section

RelevancedMMR/MSI‑H status affects pathway eligibility and checkpoint inhibitor prior‑therapy requirements

FOLFIRI — definition

DefinitionFOLFIRI = fluorouracil, leucovorin, irinotecan

UseListed as an allowed cetuximab combination for first‑line metastatic CRC

Appendix

OpenPayer

Clinical Policy: Cetuximab (Erbitux)

Coverage Criteria for Cetuximab (Erbitux)

Approved Regimens and Combinations

Required Biomarker and Mutation Status

Billing Codes and Dosing Information

Provider Requirements and Authorization

Line of Therapy Designations

Background and Drug Information

Definitions and Abbreviations